Paul Elkington
Professor
Faculty of Medicine
National Heart Lung Institute
United Kingdom
Biography
My research interest is how tuberculosis causes damage to patients' lungs. Tuberculosis continues to kill over 2 million people a year, primarily in the developing world, and lung disease not only causes spread from person to person but also causes most mortality and morbidity. Within the tuberculosis research group, we integrate analysis of clinical samples with basic scientific approaches to understand the mechanisms of disease. My research focuses on how enzymes called matrix metalloproteinases drive lung cavitation. The ultimate aim is to identify new therapeutic targets to improve tuberculosis treatment, which has remained unchanged for the last thirty years. The extracellular matrix of the lung consists of collagen and elastin fibres, which are highly resistant to breakdown. Only matrix metalloproteinases (MMPs) can degrade fibrils at neutral pH. We have shown that tuberculosis specifically up-regulates a collagenase, MMP-1. The next important question is to determine whether inhibiting this enzyme can reduce deaths from tuberculosis and allow new short course treatments.
Research Interest
tuberculosis treatment
Publications
-
Brace PT, Tezera LB, Bielecka MK, et al., 2017, Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology, Plos Pathogens, Vol:13, ISSN:1553-7366
-
Bielecka MK, Tezera LB, Zmijan R, et al., 2017, A Bioengineered Three-Dimensional Cell Culture Platform Integrated with Microfluidics To Address Antimicrobial Resistance in Tuberculosis, Mbio, Vol:8, ISSN:2150-7511